133 results about "Chemotherapy regimen" patented technology

The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and / or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.

A method of treating B-cell lymphoma comprises administering to a patient a chemotherapeutic regimen, followed by treatment with a radiolabeled anti-CD20 antibody, wherein at the time of said treatment with said radiolabeled antibody said patient is not refractory to said chemotherapeutic regimen and has not relapsed.

The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.

The efficiency of the chemotherapy of malign diseases is limited by resistances vis-à-vis the cytostatics used, which resistances are mediated by a plurality of different mechanisms that proceed at the same time or sequentially. The invention relates to the use of a method of establishing resistance profiles using RNA from tissues or cell lines by way of real-time RT PCR technology (carried out, for example, on the "Light Cycler" of Roche Diagnostics GmbH). The invention allows a quantitative analysis of the expressions of different genes that are associated with the development or the intensification or the reduction of resistances. Based thereon it is, for example, possible to establish individual patient resistance profiles that form the molecular-biological base for the selection of appropriate cytostatics before and also during the particular tumor chemotherapy. The inventive method also allows a prognosis of the chances of success (response) of certain chemotherapeutical regimes.

The invention discloses a children acute lymphoblastic leukaemia genotyping diagnosis chip. The children acute lymphoblastic leukaemia genotyping diagnosis chip is a DNA chip which is fixed with 62 DNA fragment arrays on the surface of a carrier. .The nucleotide sequences of the 62 DNA fragment arrays are respectively the sequence 1 to the sequence 62 of the sequence list. The invention further discloses a children acute lymphoblastic leukaemia genotyping method. The genetic chip of the invention can provide precise typing so as to help correctly choose a chemo-treatment plan of appropriate strength, thereby reducing complicating disease and improving curative ratio and life quality. The genetic chip of the invention can be used to carry out genotyping on childhood ALL. Therefore, the genetic chip not only saves diagnosis cost, but also has significance in protecting labour resource and promoting family and society harmony.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and / or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and / or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

Cancerous tumours vary significantly in their response to chemotherapy agents. Currently, it is difficult to reliably assess the level of tumour responsiveness to a chemotherapy regimen during or post-administration. Biomarkers of tumour sensitivity to chemotherapy agents have hitherto been unknown. Such a biomarker would expedite identification of nonresponsive patients, who may then switch to other, possibly more effective regimens. The present invention provides a method for determining tumour responsiveness to a chemotherapy agent, wherein RNA is isolated from tumour cells of a patient before, during, and after chemotherapy. The quality of the RNA can be determined by capillary electrophoresis and assignment of an RNA integrity number (RIN). RIN values during and / or after chemotherapy are inversely proportionate to the level of tumour responsiveness. The tumour RIN is an easily accessed biomarker of tumour responsiveness to chemotherapy. The tumour RIN may also be used to assess the efficacy of a chemotherapy regimen.

The present invention relates to predictive methods for use in medicine, in particular cancer chemotherapy. The purpose of the present invention is to provide a method for evaluating the expression level of ERCC1 in fixed or fixed and paraffin-embedded tissues by detecting the amount of ERCC1 mRNA in tumor cells of a patient and comparing it with a predetermined threshold expression level, and determining the platinum-based Methods of chemotherapy. More particularly, the present invention provides oligonucleotide primer pairs for ERCC1, and methods for detecting ERCC1 mRNA levels using them.

The invention relates to a cancer precise chemotherapy typing marker screening method, a chemotherapy sensitivity molecular typing method and application. According to the method, a typing marker is obtained from a multi-center and large sample queue to discover molecular typing, and a classifier is constructed by using the typing marker or differential protein obtained based on a typing label asa selection characteristic; when the classifier carries out classification application, expression profile data of a collected sample is input; and after expression spectrum data preprocessing, classifier feature matching and logarithm conversion are performed, prediction is performed by the classifier constructed through a machine learning classification algorithm or an artificial intelligence model; and finally an output label of a chemotherapy sensitive group or a chemotherapy insensitive group is obtained, and molecular typing of accurate chemotherapy is performed, so that the problem of pain spots in the field of tumor medical treatment is solved, wherein the problems comprise: accurately judging whether chemotherapy is beneficial to people, providing first-line medication regimen optimal combination recommendation and providing chemotherapy regimen optimal period recommendation.

The invention relates to a kit for the mRNA expression level of a PML-RARa fusion gene, and belongs to the field of biotechnology. The kit comprises a PML-RARa L fusion gene system, a PML-RARa V fusion gene system or a PML-RARa s fusion gene system and a reference gene system ABL, wherein each system comprises an upstream primer and a downstream primer and Taqman fluorescence probe. The PML-RARa fusion protein, as a variant retinoic acid receptor, has different DNA properties with a wild type RARa protein and is an intrinsic and effective repressor for retinoic acid (RA) signal which is the transcription factor of an intrinsic RARa target gene. Therefore, when the fluorescence quantitative polymerase chain reaction (PCR) method is used for detecting the mRNA expression level of the PML-RARa fusion gene, the detection result is more specific and sensible. The kit provides a novel quick and simple genetic diagnosis technology for predicting the prognosis of acute promyelocytic leukemia and determining chemotherapy regimens.

Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.

The invention relates to a multiple-gene detecting kit related to antitumor drugs. The multiple-gene detecting kit comprises a mixture of RT (reverse transcription) primers and a mixture of PCR (polymerase chain reaction) amplification primers, wherein each RT primer and each PCR amplification primer based on genetic groups, reference genes and a reaction internal label are respectively contained in each of the mixture of the RT primers and the mixture of the PCR amplification primers; the multiple-gene detecting kit is characterized in that the genetic groups comprise PTEN, EGFR, DPYD, HER2, RRM1, ERCC1, TUBB3, TOP1, TYMS and TOP2A; the reference genes comprise ACTB, GAPDH and B2M; the reaction internal label is KAN-rRNA (ribosomal RNA). The multiple-gene detecting kit related to antitumor drugs disclosed by the invention can be used for systemically detecting the expression level of a plurality of genes closely related to the antitumor drugs by one step, is simple and convenient to use, good in accuracy and high in detecting efficiency, and can be used for guiding chemotherapy drugs and selecting chemotherapy regimens very well.

The invention relates to a method for determining a chemotherapeutic regimen for an individual, comprising obtaining a mRNA sample from a primary tumor specimen; determining a gene expression level for a tumor gene determinant in the specimen; comparing the gene expression level for the tumor gene determinant with a predetermined threshold value for that gene; and providing a chemotherapeutic regimen comprising a chemotherapeutic agent appropriate for the tumor gene determinant to treat the tumor metastases.

The present invention provides, inter alia, kits for selecting a chemotherapy regimen for a subject. The kits comprise one or more components for detecting the expression of at least one gene from the group of SLC12A7, GZMB, TAF6L, NFIB, METRN, ROPN1B, TTK, CCND1, PTTG1, H2AFZ, WDR45L, DEK, MCM2, USP1, CDT1, TMEM97, RER1, MCM6, LZTFL1, C11orf17, CCL5, XCL1, XCL2, MELK, CTSL2, TPX2, AURKA, CDKN2C, BRP44, PNP, SMC4, NR4A2, C3orf37, MTPAP, CDC25B, ABCF1, MTAP, SNAPC3, RANBP9, COIL, FAM86B1, ITGA6, S100P, RANBP1, PRSS16, SMARCA2, STK24, TSPYL5, SRI, LRP12, CENPF, TUBD1, KIAA1324, DBF4, CCNA2, DLGAP5, FHL1, SIRT3, GTSE1, PCNA, CCNE2, CHD3, CAP1, GPM6B, GUSBP3, GNAI3, LMO4, PSRC1, USP1, STK38, BAT2L1, PMP22, NME5, CENPA, BANK1, and derivatives thereof. Methods for selecting a chemotherapy regimen for a subject are also provided.

The invention discloses a method for modeling and analyzing protein fingerprinting of advanced colorectal cancer and a kit. The steps comprises: (1) respectively establishing serum protein fingerprinting for patient samples with advanced colorectal cancer, who suffer from a chemotherapy regimen; (2) extracting serum protein fingerprint characteristics in the serum protein fingerprinting of the obtained samples, and respectively establishing standard models based on the chemotherapy regimen; (3) establishing serum protein fingerprinting for patients with advanced colorectal cancer, who do not suffer from the chemotherapy regimen, and extracting the serum protein fingerprint characteristics; and (4) contrasting and analyzing the serum protein fingerprint characteristics of the patients who do not suffer from the chemotherapy regimen, with the standard models established in the step (2). The chemotherapy regimen may be FOLFOX or FOLFIRI. The method overcomes a blindness problem of a therapeutic regimen for advanced colorectal cancer. Before chemotherapy, the serum protein fingerprinting of the patients with advanced colorectal cancer is detected, to analyze the patient is a beneficiary of the FOLFOX regimen or the FOLFIRI regimen.

The invention relates to a kit for detecting an expression index of mRNA (messager Ribose Nucleic Acid) of a WT1 (Wilms Tumor 1) gene, and belongs to the field of biotechnology. The kit comprises detection primers, a fluorescent probe, a cDNA (complementary Deoxyribose Nucleic Acid) first strand synthesis reagent, a fluorescent quantitative PCR (Polymerase Chain Reaction) mixed solution, negative reference and positive reference, wherein the detection primers and the fluorescent probe comprise a WT1 gene primer, an internal reference gene ABL primer and a Taqman fluorescent probe. The WT1 gene is related with hematopoietic tumor incidence, is of over-expression in about 80% of patients with newly diagnosed acute myelocytic leukemia and acute lymphocytic leukemia, is recognized as a leukemia marker gene, and can serve as an independent minimal residue disease monitoring and prognosis prompting index. The level of the mRNA of the WT1 gene is detected by adopting a fluorescent quantitative PCR technology with higher sensitivity and specificity, and both the specificity and the sensitivity of a detection result are remarkably improved. The kit provides a brand-new quick, simple and convenient gene diagnosis technology for prognosing the acute myelocytic leukemia and the acute lymphocytic leukemia and confirming chemotherapy regimens.

We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosphorylation. The ratio of Mig6 / EGFR expression highly correlates with erlotinib sensitivity. A low Mig6 / EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors.

The present invention relates to monitoring of ErbB receptor levels in methods and kits for determining the prognosis of cancer in a subject or improving the effectiveness of a cancer treatment. The invention also provides a method for predicting the recurrence of clinical signs of a cancer in a subject. In some embodiments, the invention provides methods for predicting the development of resistance to a chemotherapy regimen. In other embodiments, the invention provides methods for improving the effectiveness of a cancer treatment in a subject by monitoring levels of ErbB-2, ErbB-3 and / or ErbB-4. Preferably, the subject in the methods of the invention has been previously treated with a chemotherapy regimen for an ErbB-1 positive tumor.

The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.

The embodiment of the invention relates to a medical colorectal cancer data processing method and device, and belongs to the technical field of data processing. The method comprises the steps that initial colorectal cancer medical record data meeting a preset condition is obtained, and first colorectal cancer chemotherapy decision information and first colorectal cancer feature information of target colorectal cancer medical record data are obtained in the initial colorectal cancer medical record data; by using the first colorectal cancer chemotherapy decision information and the first colorectal cancer feature information, an initial model based on machine learning is trained, and an aid decision making model is obtained; by using the aid decision making model, second colorectal cancer feature information of a to-be-treated colorectal cancer patient is predicted, and second colorectal cancer chemotherapy decision information of the to-be-treated colorectal cancer patient is obtained.By means of the method, the problem that in the prior art, a medical scheme is recommended based on a rule tree, and accordingly the accuracy is low is solved, and the colorectal cancer chemotherapy scheme recommendation accuracy is improved.

The present invention is directed to methods for the treatment of Hodgkin's lymphoma comprising administering to a patient in need thereof, a therapeutically effective amount of 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6 -(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide as mono-therapy or as combination or co-therapy with one or more chemotherapeutic agent or chemotherapy regimens.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing HER2-neu and / or EGFR expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable sensitivity of a patient's tumor to treatment with receptor tyrosine kinase targeted chemotherapy by examination of the amount of HER2-neu and / or EGFR mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs EGFR and HER2-neu and methods comprising their use for detecting levels of EGFR and HER2-neu mRNA, respectively.

The invention discloses novel markers for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer and its application. Specifically, the invention provides a set of the markers for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer and its use in a product for predicting the efficacy of pemetrexed-platinum combined treatment on non-small cell lung cancer. The markers comprise hypotaurine, uridine, dodecanoyl carnitine, choline, dimethyl glycine, nicotinamide and hexadecanoyl carnitine. The markers and a modelwith the markers can predict the efficacy of the chemotherapy scheme before the patient undergoes chemotherapy and has sensitivity of 90.8% and specificity of 79.5%.

The invention discloses an application of a reagent for detecting gene expression level and a construction method of an NAC (neoadjuvant chemotherapy) curative effect prediction model for breast cancer patients, and relates to the technical field of breast cancer. Particularly, the prediction model can predict the curative effect of anthracyclines and taxus drugs in NAC, so as to provide a basis for whether the breast cancer patients accept NAC regimens or choose which type of NAC regimens. The patients who are sensitive to chemotherapy regimens and may reach pCR can seize the opportunity of NAC by predicting the curative effect, so that effective NAC is conducted, and the breast-conserving rate or survival rate is increased; however, the patients who are insensitive to chemotherapy regimens or may cause tumor progression can choose other effective treatments in time.

The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and an adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with a radiation therapy or chemotherapy regimen.

The invention discloses application of perhexiline / oxaliplatin drug combination in the aspect of treatment of stomach cancer and colorectal cancer. The research shows that the perhexiline is capable of obviously inhibiting the growth, proliferation and clone formation capacities of the stomach cancer and colorectal cancer cells, inducing the apoptosis of the stomach cancer and colorectal cancer cells and inhibiting the invasion and transfer capacities of the stomach cancer and colorectal cancer cells, has obvious treatment effects on stomach cancer and colorectal cancer, and therefore, can be used in drugs for treating stomach cancer and intestinal cancer. The invention provides new application of perhexiline, thereby widening the clinical application fields of perhexiline; and the invention also provides a new scheme of perhexiline / oxaliplatin drug combination in treating stomach cancer and colorectal cancer, thereby increasing the options for chemotherapeutic schemes of stomach cancer and colorectal cancer, and having favorable clinical application prospects.

The anticancer Chinese medicine orally taken preparation has the recipe comprising Chinese fanpalm seed 2-14 (in weight portions, the same below), common camptotheca seed 1-10, zedoary 2-6, bupleurum root 2-6, gynostemma pentaphylla 2-6, Xianggu mushroom 0-3, astragalus root 0-6 and licorice 0-1. The animal test and the clinical test show that the medicine can promote blood circulation to disperse blood clots, invigorate spleen and remove food stagnancy, has obvious auxiliary treating and synergistic effect on radiotherapy and chemotherapy, and can improve the clinical symptoms of liver cancer and stomach cancer.

The present invention relates to the use of p53 gene therapy to treat recurrent cancers in combination with a radio- or chemotherapy. Patients with recurring cancers are treated with a p53 expression construct followed by subsequent radio- or chemotherapy treatment. Viral and non-viral delivery systems, as well as various radio- and chemotherapy regimens are disclosed.